Morgan Stanley Maintains Si-Bone(SIBN.US) With Buy Rating, Cuts Target Price to $19
Analyst Ratings For SI-BONE
A Quick Look at Today's Ratings for Si-Bone(SIBN.US), With a Forecast Between $18 to $32
Buy Rating Maintained for SI-Bone Amid Strong Q2 Performance and Promising Growth Outlook
Truist Financial Remains a Buy on SI-Bone (SIBN)
SI-BONE Analyst Ratings
Buy Rating Affirmed: SI-Bone's Financial Success and Growth Trajectory Outshine Market Expectations
SI-BONE Analyst Ratings
Morgan Stanley Lowers Price Target on SI-Bone to $21 From $25, Keeps Overweight Rating
SI-BONE Analyst Ratings
Positive Outlook for SI-Bone: Robust Revenue Growth and Strategic Advances Reinforce Buy Rating
Morgan Stanley Trims Price Target on SI-Bone to $25 From $26, Keeps Overweight Rating
SI-BONE Analyst Ratings
SI-Bone's Strong Start and Revenue Growth Potential Affirm Buy Rating
JMP Securities Reaffirms Their Buy Rating on SI-Bone (SIBN)
Piper Sandler Keeps Their Buy Rating on SI-Bone (SIBN)
Analysts' Opinions Are Mixed on These Healthcare Stocks: SI-Bone (SIBN), Conmed (CNMD) and Chemed (CHE)
Truist Financial Sticks to Their Buy Rating for SI-Bone (SIBN)
SI-BONE Analyst Ratings
SI-Bone's Favorable Outlook and Buy Rating Amidst Stable Medical Coverage and Growth Prospects
No Data